Engitix
Business Services · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
The Westworks 195 Wood Ln Fl 4, London, ...Phone Number
+44 2045307654Website
www.engitix.comRevenue
$14.2 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Engitix
Founded in 2016, Engitix a British biopharmaceutical company has already developed a platform for discovering human extracellular matrix drug target. Engitix has developed a portfolio of programs in fibrosis and solid tumors and two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform. The company is headquartered in London, United Kingdom.Explore more
Engitix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Engitix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Engitix, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Engitix
Click to see if Engitix had a recent Job posting/layoffs
Product Launch: Get notified when Engitix launches new products
Check out if Engitix is spiking on competitors!
Funding: Get notified immidiatlly once Engitix has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Engitix has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Engitix recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Engitix
Compare insights from companies similar to Engitix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Engitix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Engitix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Engitix.
Engitix financials insights
Gather financial insights about Engitix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$60.2M
2026
Series A
$25M
Engitix Tech Stack
A closer look at the technologies used by Engitix
Most Recent Scoops
Person-Based
Partnership, Product Development
Person-Based
Giuseppe Mazza stating the partnership strengthens their efforts to develop more precise treatments.
Partnership
Person-Based
Medical Research
Funding
Funding
Funding
Engitix News & Media
Lonza and Engitix Announce License Agreement to Advance Targeted ADC Development
BASEL, Switzerland and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Lonza, the world's leading contract development and manufacturing organization (CDMO), and Engitix, a global leader in ECM-based drug discovery and development, today announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs) and deliver life-changing therapies for patients with chronic diseases.Engitix Announces Strategic Collaboration with GSK to Advance First-in-Class Targets for Liver Fibrosis Regression
Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regression Collaboration leverages Engitix’s human ECM Platform to identify high-confidence targets for liver fibrosis regressionEngitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis
Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumorsEngitix appoints two additional international biotech industry leaders as Scientific Advisors
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of two biotech industry leaders as Scientific Advisors: Adrian S. Ray, PhD, and Scott Turner, PhD.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Engitix
Sign Up For FreeTo access detailed company insights
Founded in 2016, Engitix a British biopharmaceutical company has already developed a platform for discovering human extracellular matrix drug target. Engitix has developed a portfolio of programs in fibrosis and solid tumors and two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform... Read More
